Takashi Kumamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Takashi Kumamoto has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Akiko Seki
Department of Cardiology Tokyo Women's Medical University Tokyo Japan
1 shared publication - Arthur Arnold Maria Wilde
ERN GUARD‐Heart Amsterdam the Netherlands
1 shared publication - Hitoshi Mori
Department of Cardiology Saitama Medical University International Medical Center Hidaka Saitama Japan
1 shared publication - Jean-Jacques Schott
Nantes Université, CHU Nantes, CNRS, INSERM, l’institut du thorax , F-44000 Nantes
1 shared publication - Naokata Sumitomo
Department of Pediatric Cardiology Saitama Medical University International Medical Center Saitama Japan
1 shared publication - Naomasa Makita
Department of Cardiology Sapporo Teishinkai Hospital Sapporo Japan
1 shared publication
Latest Publications
- Open Access
- 25 June 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (3) , e70383
Current Topics of Progressive Cardiac Conduction Disease
Progressive cardiac conduction disease (PCCD) is a rare inheritable cardiac conduction system disease that may lead to complete heart block, syncope, or sudden cardiac death. The estimated incidence of PCCD is 0.0005%/year. Recent advances in genetics have revealed a wide variety of diseases associated with the development of PCCD. Ion channel genes ( SCN5A, KCNK17, TRPM4, HCN4 ), gap junction genes ( GJA5 , GJC1 ), genes associated with myopathy ( LMNA , EMD , DES , DMD , TNNI3K , DMPK, ZNF9 ), transcription factor genes ( NKX2‐5 , TBX5 ), genes associated with metabolic disease ( PRKAG2 , LAMP2 , GLA ), and mitochondrial gene variants have all been associated with the occurrence of PCCD. Pacemaker implantation is the first‐line therapy for PCCD, but implantable cardioverter defibrillator implantation should be considered in some cases. This review aims to provide a clinically relevant overview of these different forms, with emphasis on their genetic basis and phenotypic expression. We propose a practical classification distinguishing isolated and associated forms of PCCD and discuss the implications for diagnosis, risk stratification, and patient management.
- 25 June 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (3) , e70383
Open AccessCurrent Topics of Progressive Cardiac Conduction Disease
Progressive cardiac conduction disease (PCCD) is a rare inheritable cardiac conduction system disease that may lead to complete heart block, syncope, or sudden cardiac death. The estimated incidence of PCCD is 0.0005%/year. Recent advances in genetics have revealed a wide variety of diseases associated with the development of PCCD. Ion channel genes ( SCN5A, KCNK17, TRPM4, HCN4 ), gap junction genes ( GJA5 , GJC1 ), genes associated with myopathy ( LMNA , EMD , DES , DMD , TNNI3K , DMPK, ZNF9 ), transcription factor genes ( NKX2‐5 , TBX5 ), genes associated with metabolic disease ( PRKAG2 , LAMP2 , GLA ), and mitochondrial gene variants have all been associated with the occurrence of PCCD. Pacemaker implantation is the first‐line therapy for PCCD, but implantable cardioverter defibrillator implantation should be considered in some cases. This review aims to provide a clinically relevant overview of these different forms, with emphasis on their genetic basis and phenotypic expression. We propose a practical classification distinguishing isolated and associated forms of PCCD and discuss the implications for diagnosis, risk stratification, and patient management.